求助6篇Springer数据库文献

w2503

1. Clinical Applications of Activated Immune Cells2 C3 a" O! ~* k1 R+ g
http://www.springerlink.com/content/p77j27781g92vm53/
! V! a  m; m. j+ h1 U; h$ |' K3 V% J: Q) g4 E: c: J
2. Increased effector–target cell conjugate formation due to HLA restricted specific antigen recognition
; ]% O# x# @1 N, W+ G! mhttp://www.springerlink.com/content/l667677h47l82363/8 r. S4 i8 h$ T. f$ {0 T4 f

2 ?2 D! ^7 e2 d* {+ R4 J3. Selective Immortalization of Tumor-Specific T Cells to Establish Long-Term T-Cell Lines Maintaining Primary Cell Characteristics
2 B5 N6 W+ s3 e& R5 c! J' o! z6 _http://www.springerlink.com/content/lg3m7811288qg086/#section=54582&page=1
: v7 o. M2 t6 j3 ^2 m( @3 f7 w/ ]9 g; o3 c! m& O
4. Extending the Use of Adoptive T Cell Immunotherapy for Infections and Cancer6 b$ ~& @! l) L" f7 s" d
http://www.springerlink.com/content/u67186375261m831/+ K: \5 w, s) d
4 Y; Z$ n! X# b
5. Gene Immunotherapy for Non-Small Cell Lung Cancer
: M$ k% D: P& p: V1 v& G( l9 Z" jhttp://www.springerlink.com/content/w2j70l9rx1857154/#section=671351&page=17 b  ^5 d. v- y1 c; Q  ~3 C

" a0 o. \# Y9 ^; K& q6. Designing TCR for Cancer Immunotherapy0 X0 [# _$ S' O
http://www.springerlink.com/content/v7607l2v0243k7m7/#section=83660&page=1
* S2 x8 n" J/ G, l8 g& ?4 _5 r4 r6 h# _1 ~: k+ m1 |+ @/ [
谢谢2 V4 Q/ [$ f" Y0 h8 f& C
& Q6 K2 r; X: F- c! r
9 [% z9 h; A2 B) O! Q) x

9 ]2 V/ r4 G6 y. b# {! \
; l6 ~2 ~  c2 x5 \

w2503

回复 sunlu36 的帖子
% u/ T) j# \. f" m1 B
+ S  ]8 q; Z  }( w0 D6 D谢谢

w2503

' l4 U2 V( T! p
; i" p( _1 G, ^7 S0 H; m% T还差第2篇" D5 E7 o( l6 X2 j9 C6 {* x! o! K3 [* C
2. Increased effector–target cell conjugate formation due to HLA restricted specific antigen recognition
7 \# }( O1 [& b( j# M7 Z( D4 ^http://www.springerlink.com/content/l667677h47l82363/

w2503

回复 ceming 的帖子& R8 Z0 }, l) b2 d
- h: f; ?; {1 T+ a
谢谢